The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the underwriters in connection with the $188 million upsized initial public offering of 11,730,000 shares of common stock of MBX Biosciences, Inc., which reflects the full exercise of the underwriters’ over-allotment option. The common stock is listed on the Nasdaq Global Select Market under the symbol “MBX.”

MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. MBX Biosciences was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, MBX Biosciences designed its proprietary Precision Endocrine Peptide platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Arisa Akashi Sin and Jenny Li. Partner David R. Bauer and associates Jordan Khorshad and Kimberly Hickey provided intellectual property advice. Partner Mario J. Verdolini and associates Alanna Phillips and David J. Beer provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post